2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-139377
    4-Methoxy-α-pyrrolidinopropiophenone hydrochloride 1794760-01-2 98%
    4-Methoxy-α-pyrrolidinopropiophenone hydrochloride is a biomolecule.
    4-Methoxy-α-pyrrolidinopropiophenone hydrochloride
  • HY-139388
    Para-fluoro methylaminorex 1364933-64-1 98%
    Para-fluoro methylaminorex is a neuroactive compound.
    Para-fluoro methylaminorex
  • HY-139406
    1,2-Dioctanoyl-sn-glycero-3-phospho-(1'-myo-inositol-4'-phosphate) ammonium 1246303-11-6 98%
    1,2-Dioctanoyl-sn-glycero-3-phospho-(1'-myo-inositol-4'-phosphate) (PtdIns-(4)-P1 (1,2-dioctanoyl)) ammonium is a synthetic phosphatidylinositol. 1,2-Dioctanoyl-sn-glycero-3-phospho-(1'-myo-inositol-4'-phosphate) ammonium can be used for the research of signal transduction research.
    1,2-Dioctanoyl-sn-glycero-3-phospho-(1'-myo-inositol-4'-phosphate) ammonium
  • HY-139568
    Deutarserine 103292-62-2 98%
    Deutarserine is a deuterium modified analog of endogenous D-serine (CTP 692), which is used in the research of adults with schizophrenia.
    Deutarserine
  • HY-13956C
    (R)-Pioglitazone 959687-65-1 98%
    (R)-Pioglitazone ((+)-pioglitazone) is the R enantiomer of Pioglitazone (HY-13956). (R)-Pioglitazone is an orally active and selective peroxisome proliferator-activated receptor (PPARγ) agonist with high affinity binding to the PPARγ ligand-binding domain. (R)-Pioglitazone can be used for the research of Alzheimer's disease.
    (R)-Pioglitazone
  • HY-139629
    ANAT inhibitor-1 331751-78-1 98%
    ANAT inhibitor-1 is a human aspartate N-acetyltransferase (ANAT) inhibitor for canavan disease.
    ANAT inhibitor-1
  • HY-139677
    5-HT7R antagonist 1 2759919-13-4 98%
    5-HT7R antagonist 1 is a G protein-biased antagonist against 5-HT7R (Ki = 6.5 nM).
    5-HT7R antagonist 1
  • HY-139680
    Dopamine D3 receptor antagonist-1 3052236-36-6 98%
    Dopamine D3 receptor antagonist-1 is a dopamine D3 receptor-selective or multitarget bitopic ligand (Ki = 1.58 nM) potentially useful for central nervous system disorders.
    Dopamine D3 receptor antagonist-1
  • HY-139681
    Dopamine D3 receptor antagonist-2 3052236-39-9 98%
    Dopamine D3 receptor antagonist-2 is a dopamine D3 receptor-selective (Ki = 2.16 nM) or multitarget bitopic ligand potentially useful for central nervous system disorders.
    Dopamine D3 receptor antagonist-2
  • HY-139708
    NMDA receptor antagonist-3 2762181-52-0 98%
    NMDA receptor antagonist-3, a NMDA receptor antagonist, stands out with a remarkable percentage of recovery (40.0%, at 100 μM) and safe toxicological profile in SH-SY5Y and human adipose mesenchymal stem cells.
    NMDA receptor antagonist-3
  • HY-139720
    β-Secretase Inhibitor III 2760674-85-7 98%
    β-Secretase Inhibitor III is an extremely selective BACE1 inhibitor (Ki = 0.13 nM).
    β-Secretase Inhibitor III
  • HY-139723
    Antidepressant agent 2 2822600-09-7 98%
    Antidepressant agent 2 exerts pronounced antidepressant activity (MED 0.1 mg/kg).
    Antidepressant agent 2
  • HY-139730
    c-ABL-IN-1 2304918-82-7 98%
    c-ABL-IN-1 is a novel selective c-Abl inhibitor that prevents neurodegeneration in parkinson’s disease.
    c-ABL-IN-1
  • HY-139740
    Aβ Fibrillization modulator 1 2847131-53-5 98%
    Aβ Fibrillization modulator 1 stabilizes Aβ monomers.
    Aβ Fibrillization modulator 1
  • HY-13976A
    PRL-8-53 51352-87-5 98%
    PRL-8-53 is a derivative of 2-PhenylethylaMine. PRL-8-53 is an orally active psychotropic agent.
    PRL-8-53
  • HY-139816
    BTNPO 2507992-93-8 98%
    BTNPO is a unimolecular two-photon fluorescent probe.
    BTNPO
  • HY-139820
    FTO-IN-4 2763577-74-6 98%
    FTO-IN-4 is a potent and selective inhibitor of fat mass obesity-associated protein (FTO).
    FTO-IN-4
  • HY-139821
    FTO-IN-5 2763577-75-7 98%
    FTO-IN-5 is a potent and selective inhibitor of fat mass obesity-associated protein (FTO).
    FTO-IN-5
  • HY-139830
    Dyrk1A-IN-1 2858696-72-5 98%
    Dyrk1A-IN-1 is a triple inhibitor of Dyrk1A kinase activity (IC50 = 119 nM) and the aggregation of tau and α-syn oligomers.
    Dyrk1A-IN-1
  • HY-139871
    hTrkA-IN-2 2986533-14-4 98%
    hTrkA-IN-2 is a selective hTrkA allosteric inhibitor with an IC50 value of 3.9 nM.
    hTrkA-IN-2
Cat. No. Product Name / Synonyms Application Reactivity